Schroders plc half-year results

Schroders Plc, uno dei principali gruppi finanziari globali con focalizzazione esclusiva sulla gestione di capitali, quotato alla Borsa di Londra dal 1959 e parte dell’indice FTSE 100, ha chiuso il primo semestre del 2022 con un aumento del risultato operativo netto a 1.240,3 milioni di sterline, dato che evidenzia la resilienza del business della società. L’utile operativo è aumentato del 2% a 406,9 milioni di sterline. La performance d’investimento si è mantenuta solida, con il 77% dei patrimoni dei clienti che ha sovraperformato il relativo comparatore a tre anni e il 79% a cinque anni. Sono state generate nuove attività nette per 8,4 miliardi di sterline, che hanno contribuito a far crescere il patrimonio in gestione fino a 773,4 miliardi di sterline (EUR 898,4 miliardi). Escludendo le joint venture e le società collegate, le nuove attività nette generate sono state pari a 4,4 miliardi di sterline e il patrimonio in gestione ha raggiunto i 637,5 miliardi di sterline. “Abbiamo costruito un’attività diversificata e resiliente che ci ha consentito di superare le difficoltà legate alle condizioni di mercato, e che è in grado di finanziare la crescita, ponendoci in una posizione eccellente per servire i nostri clienti. Ne è testimonianza il fatto che in questo periodo registriamo un dato positivo in termini di Net New Business (Nuove attività nette acquisite). L’investimento in sostenibilità ha contribuito in modo determinante al nostro successo. È stato particolarmente evidente nel business dei fondi comuni d’investimento dove, nonostante le forti vendite nelle borse, i nostri fondi azionari hanno registrato afflussi positivi di capitale. Le nostre attività di private assets, wealth e solutions stanno crescendo bene, rafforzando il valore del nostro focus strategico. È questa diversificazione che ci consente di continuare a soddisfare le esigenze in continua evoluzione dei nostri clienti”.

Halo Collective Announces Preliminary Results for North Hollywood

Toronto. Halo Collective Inc. (“Halo” or the “Company”) (NEO: HALO) (OTCQB: HCANF) (Germany: A9KN) announced continued progress in its Budega retail growth strategy in Los Angeles, including strong preliminary store level performance for its first dispensary in North Hollywood (NOHO) and a firm “Grand Opening” date for its second dispensary in Westwood on May 27, 2022. Budega North Hollywood (“NOHO”) is generating strong store level performance highlighted by a nearly 300% increase in gross sales in April as compared to the first month of operations in March. NOHO’s growth is being driven by positive trends in store metrics such as foot traffic, ticket numbers and basket size. Additionally, 96% of customers are enrolling in Budega’s loyalty program. To further improve store performance Halo is planning the imminent full launch of Budega Delivery which the Company anticipates will add 33% to topline sales. Commented Beau McKeon, SVP of Retail Operations, “Budega Noho is off to a promising start in only its second month of operation, with gross sales tripling and almost all of our customers joining our loyalty program. It’s clear that the community has welcomed us as a new neighbor, and we continue to build momentum with market share.” Halo has continued to evolve and innovate Budega’s in-store customer experience, elevating the normal “weed” transaction. The Company’s marketing and store operations teams have collaborated and executed captivating campaigns like “Weed Love to Meet You” that invite, inspire and compel customers to make Budega part of their daily routine. Additionally, Budega continues to offer a product assortment exceeding 1,000 SKUs, including many top-tier California brands such as Jungle Boys, Cookies, Kiva and the customer favorite Budega-branded product lineup. Budega dispensaries will also stock Halo’s Hush™ branded cartridges, gummies, and pre-rolls. Added Katie Field, President of Halo, “Budega’s early success is due to our laser focus on guest service standards and commitment to providing vast product assortment. By placing customers first and creating an inviting and welcoming shopping experience, we have instilled loyalty and for that we are deeply grateful. We expect that by building our customer relationships local market share will continue to shift to Budega.” Both the North Hollywood and Westwood stores operate Monday through Sunday from 7 a.m. to 10 p.m. Visit http://www.budega.com for more information.

Hope Bancorp to Announce 2019 Fourth Quarter Financial Results

Hope Bancorp, Inc. (NASDAQ: HOPE) today announced that the company will announce financial results for its 2019 fourth quarter after the markets close on Wednesday, January 22, 2020.A conference call to discuss 2019 fourth quarter financial results will be held on Thursday, January 23, 2020 at 9:30 a.m. Pacific Time / 12:30 p.m. Eastern Time. A presentation deck to accompany the earnings call will be available at the Investor Relations section of Hope Bancorp’s website at http://www.ir-hopebancorp.com. After the live webcast, the archived webcast will remain available in Hope Bancorp’s investor relations website for one year.
Hope Bancorp, Inc. is the holding company of Bank of Hope, the first and only super regional Korean-American bank in the United States with $15.4 billion in total assets as of September 30, 2019. Headquartered in Los Angeles and serving a multi-ethnic population of customers across the nation, Bank of Hope operates 58 full-service branches in California, Washington, Texas, Illinois, New York, New Jersey, Virginia, Georgia and Alabama. The Bank also operates SBA loan production offices in Seattle, Denver, Dallas, Atlanta, Portland, Oregon, New York City, Northern California and Houston; commercial loan production offices in Northern California and Seattle; residential mortgage loan production offices in Southern California; and a representative office in Seoul, Korea. Bank of Hope specializes in core business banking products for small and medium-sized businesses, with an emphasis in commercial real estate and commercial lending, SBA lending and international trade financing. Bank of Hope is a California-chartered bank, and its deposits are insured by the FDIC to the extent provided by law. Bank of Hope is an Equal Opportunity Lender. For additional information, please go to bankofhope.com.

Tartalife Turtle Safe Project Produces Results for Friend of the Sea and Partners

The TartaLife Project, which includes the “Turtle Safe” certification from Friend of the Sea, is producing impressive results as it heads into its sixth year of operation. The program has resulted in substantial reductions in deadly “bycatch” of turtles in commercial fishing, the publication of scientific papers and more. Friend of the Sea is the leading worldwide certification standard for products and services that respectand protect the marine environment. The organization is a project consultant in the TartaLife Project.
The Mediterranean hosts large numbers sea turtle species, including the loggerhead turtle (Caretta caretta) and the green turtle (Chelonia mydas). Unfortunately, sea turtles were getting caught in fishing nets at the rate of 40,000 per year—10,000 of which died. Friend of the Sea and its partners in TartaLife felt that urgent action was needed to prevent an environmental catastrophe.
To address the crisis, the TartaLife project was launched in 2013 with the goal of reducing the loggerhead turtle mortality from commercial fishing. The project also intended to contribute to the species’ conservation in the Mediterranean Sea.The project was funded by the EU through the LIFE + NATURA 2012 fund, it was co-financed by the Marche Region and supported by the Italian Ministry of Agricultural, Food and Forestry Policies and Tourism – General Fisheries Directorate (MIPAAFT) and involved the15 Italian coastal regions.In six years, TartaLife has produced impressive results. These include a 100% reduction in turtle bycatch obtained with TEDs, a 100% reduction in turtle bycatch obtained with UV-LED lamps and collapsible fish pots and a 30% reduction of turtle bycatch obtained using circle hooks, with reduction of direct mortality. More than 1,500 turtles have been rescued by TartaLife Centers.
“This step towards the certification of the fish product is essential in order to reach the recognition of the activity done and to undertake the path towards the diffusion of low impact devices among fishermen” said Alessandro Lucchetti, Project Coordinator (CNR-IRBIM).The project has held more than 6,000 public events, engaging with 53 vessels and 239 fishermen in sea trials testing of circle hooks. Thirty-three vessels and180 fishermen were involved in sea trials testing TEDs. Over 500 fishermen participated in information seminars, with 704 attending first aid seminars.The program has reached more than one million tourists, with TartaLife publishing 10,000 press releases and 100 reports. The group has published eight papers in international scientific journals.
As part of the project, Friend of the Sea worked with its partners to devise the “Turtle Safe” logo, which is analogous to the world-famous Dolphin Safe brand. This is the first label identifying fishing activities that have a low impact on sea turtles inthe entire Mediterranean. The new brand will be unveiled by Friend of the Sea, whowill own it throughout the Mediterranean.

TiVo Corporation Announces 2019 Q2 Results and Conference Call

TiVo Corporation (NASDAQ: TIVO) announced today that it plans to release its 2019 second quarter results on July 31, 2019. TiVo also plans to host a conference call at 5:00 p.m. ET on July 31, 2019 to discuss its financial results. Investors and analysts interested in participating are welcome to call (866) 621-1214 (or international +1-706-643-4013) and reference conference ID 8448589. The conference call may also be accessed via live webcast in the Investor Relations section of TiVo’s website at http://ir.tivo.com/.A replay of the audio webcast will be available on TiVo’s website shortly after the live call ends, and we currently plan for it to remain on TiVo’s website until the next quarterly earnings call. Additionally, a telephonic replay of the call will be accessible shortly after the live call ends through August 7, 2019

Innovus Pharma Releases Results from Annual Shareholders Meeting

Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB Venture Market: INNV), an emerging over-the-counter (“OTC”) consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases, today released the final voting results from the Annual Shareholders Meeting held on May 28, 2019.
Votes were cast by 1,402,506 (54.3%) of the total 2,581,486 shares that were issued and outstanding on the record date of April 25, 2019, and as such were eligible to vote. The shareholders voted on four matters: (1) the re-elections of Dr. Bassam Damaj, Dr. Henry Esber, Mr. Dean Nuhaily, Ms. Vivian Liu, and Mr. Ziad Mirza to the Company’s Board of Directors, (2) the ratification of Hall and Company, Inc., as the Company’s auditors for 2019, (3) the advisory vote on the approval of compensation of the named executive officers of the Company, and (4) the approval of the Company’s 2019 Equity Incentive Plan.

Abeona Therapeutics Reports First Quarter 2019 Financial Results and Business Highlights

NEW YORK and CLEVELAND (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced first quarter 2019 financial results and business highlights, which will be discussed on a conference call scheduled for Tuesday, May 14 at 10:00 a.m. ET. “We’ve had a great start to 2019, with continued progress across our pipeline, including the completion of CMC work in advance of initiating our Phase 3 VITAL™ clinical trial evaluating EB-101, our gene-corrected cell therapy for patients with recessive dystrophic epidermolysis bullosa,” said João Siffert, M.D., Chief Executive Officer. “The study, which will utilize clinical material produced at our Cleveland manufacturing facility, is on track to start mid-2019 following completion of ongoing FDA review.”“We have continued to advance our lysosomal storage disease programs. Our increased efforts around patient recruitment are starting to bear fruit as we observe an uptick in patient screening for both MPS programs. In addition, we have submitted the IND for our CLN1 program.” added Dr. Siffert.First Quarter Financial Results:
Cash, cash equivalents and marketable securities as of March 31, 2019 were $68.3 million, compared to $85.0 million as of December 31, 2018. The decrease in cash of $16.7 million was driven primarily by the net cash used for operating activities of $15.1 million.
Research and development expenses for the first quarter ended March 31, 2019 were $11.7 million, compared to $8.2 million for first quarter 2018. The increase in research and development expense was primarily attributable to increased R&D headcount, related facility costs and internal manufacturing costs.
General and administrative expenses for the first quarter ended March 31, 2019 were $5.7 million, compared to $2.9 million for the first quarter 2018. The increase in general and administrative expenses was primarily attributable to increased headcount and related facility costs.
Net loss was $0.39 per share for the first quarter of 2019, compared to $0.22 per share in the same period of 2018.

DexYP Announces Results of Tender Offer

DexYP®, a leading small business software provider, announced today the results of its tender offer, which previously expired at 10:00 a.m. Eastern Time on April 23, 2019 (the “Expiration Date”).DexYP raised new credit facilities in late 2018, and early 2019, the funds from which could be used for a variety of uses, including to launch a tender offer. On March 25, 2019 DexYP launched a tender offer to purchase up to 42,650,000 shares of common stock of DexYP (“Shares”) and up to 2,780,000 in vested and unexercised options to purchase Shares (“Options”) at $10.15 per Share and/or Option for an aggregate purchase price of $461,114,500.Following the Expiration Date, DexYP has reviewed the results of the tender offer, which was oversubscribed. Accordingly, DexYP has decided, pursuant to the terms of the tender offer, to exercise its right to accept for repurchase additional Share and Options up to 2% of the outstanding shares of Common Stock on a fully diluted basis, in each case on a pro rata basis. In total DexYP, accepted for repurchase (i) 43,114,970 Shares for up to $437,616,946 in aggregate value and (ii) 4,186,891 Options for up to $42,496,944 in aggregate value, for an aggregate value for both Shares and Options of up to $480,113,890, which repurchase shall be subject to adjustment to avoid the purchase of fractional Shares and/or Options (and shall be undertaken on a pro rata basis). The tender offer was oversubscribed and the Shares and Options were accepted, pursuant to the terms of the tender offer (a) subject to proration and (b) increased to reflect the Company’s decision to exercise its right pursuant to the terms of the tender offer to accept for repurchase additional Shares and Options up to 2% of the outstanding shares of Common Stock on a fully diluted basis, in each case on a pro rata basis.
Payment for the properly tendered Shares and Options that were accepted for purchase is expected to commence in the first week of May. Following the transaction, the amount of DexYP common stock outstanding is anticipated to be reduced from 103,196,920 shares to 60,081,950, subject to adjustment to avoid the purchase of fractional Shares and/or Options.

Results of The Semi-Final Allocation Draw at the Tel Aviv Museum of Art

Tel Aviv. The Semi-Final Allocation Draw and the Host City Insignia Handover Ceremony marked the first official Eurovision 2019 event in Tel Aviv. The Ceremony was held at the Tel Aviv Museum of Art, one of Israel’s leading art and culture institutions, in the presence of The Mayor of Tel Aviv-Yafo, Ron Huldai, The Deputy Mayor of Lisbon, Duare Cordeiro, The Executive Supervisor of the Eurovision Song Contest, Jon-Ola Sand and the Director General of KAN, Eldad Koblenz.The event opened with the handing over of the Host City insignia from last year’s hosts, Lisbon to this year’s Host City, Tel Aviv. It is a Eurovision tradition for each Host City to add an iconic insignia to the key chain, before handing over the entire collection of insignia to the next host city.After the handing over of the Host City Insignia, the Semi-Final Allocation Draw took place, determining the order of appearance in the two semi-finals of the Eurovision Song Contest, which will take place at EXPO Tel Aviv on the 14th and 16th of May. Countries will compete for a place in the Eurovision Song Contest Finals, which will take place on Saturday, May 18th.The first part of the draw determined in which Semi-Final each of the six pre-qualified ‘Big Five’ countries (France, Germany, Italy, Spain, the United Kingdom) and host country Israel will vote.The second draw then decided in which Semi-Final each of the other participating countries will perform. The 36 Semi-Finalists were allocated into six pots, based on historical voting patterns as calculated by the contest’s official televoting partner Digame.At the request of Swiss broadcaster SRF, and following approval from the Reference Group, the governing body of the Eurovision Song Contest, Switzerland will participate in the Second Semi-Final on Thursday the 16th of May.

FLEETCOR Technologies to Announce Second Quarter 2018 Results on August 2, 2018

FLEETCOR Technologies, Inc. (NYSE:FLT), today announced that the Company will host a conference call to discuss second quarter financial results on Thursday, August 2, 2018 at 5:00 pm ET. Hosting the call will be Ron Clarke, chief executive officer, Eric Dey, chief financial officer and Jim Eglseder, investor relations. A press release with second quarter financial results will be issued after the market close that same day. The conference call can be accessed live over the phone by dialing (877) 407-0784, or for international callers (201) 689-8560. A replay will be available one hour after the call and can be accessed by dialing (844) 512-2921 or (412) 317-6671 for international callers; the conference ID is 13681872. The replay will be available until Thursday, August 9, 2018. The call will be webcast live from the Company’s investor relations website at http://investor.fleetcor.com/.FLEETCOR Technologies (NYSE:FLT) is a leading global provider of commercial payment solutions. The Company helps businesses of all sizes better control, simplify and secure payment of their fuel, toll, lodging and other general payables. With its proprietary payment acceptance networks, FLEETCOR provides affiliated merchants with incremental sales and loyalty. FLEETCOR serves businesses, partners and merchants in North America, Latin America, Europe, and Australasia. For more information, please visit http://www.FLEETCOR.com.

Boston Properties to Release Second Quarter 2018 Financial Results

Boston Properties, Inc. (NYSE: BXP), one of the largest public owners and developers of office buildings in the United States, announced today that it will release financial results for the Second Quarter of 2018 on Tuesday, July 31, 2018 after the close of trading on the New York Stock Exchange. The Company will host a conference call and audio webcast, both open to the general public, at 10:00 A.M. Eastern Time on Wednesday, August 1, 2018 to discuss the financial results for the Second Quarter and provide a Company update. The conference call can be accessed by dialing 877-706-4503 (Domestic) or 281-913-8731 (International) and entering the passcode 6696808. The replay will be available through August 22, 2018 by dialing 855-859-2056 (Domestic) or 404-537-3406 (International) and entering the passcode 6696808. There will also be a live audio webcast of the call, which may be accessed in the Investor Relations section of the Company’s website at http://www.bostonproperties.com. Shortly after the call, a replay of the webcast will be available in the Investor Relations section of the Company’s website and archived for up to twelve months following the call.Boston Properties is a fully integrated real estate investment trust that develops, redevelops, acquires, manages, operates and owns a diverse portfolio of primarily Class A office space totaling 50.3 million square feet and consisting of 167 office properties (including eight properties under construction), six residential properties (including four properties under construction), five retail properties and one hotel. The Company is one of the largest public owners and developers of Class A office properties in the United States, concentrated in five markets – Boston, Los Angeles, New York, San Francisco and Washington, DC. http://www.bostonproperties.com.

Pulse Biosciences to Report Second Quarter 2018 Financial Results and Operational Highlights

Pulse Biosciences, Inc. (Nasdaq: PLSE), a medical technology company developing a proprietary therapeutic tissue treatment based on its Nano-Pulse Stimulation (NPS) platform, today announced that the Company will report second quarter 2018 operational highlights and financial results on Tuesday, July 31, 2018. Pulse Biosciences management will host a conference call and webcast at 4:30 p.m. Eastern Time (ET) / 1:30 p.m. Pacific Time (PT).
Pulse Biosciences is a publicly listed clinical stage electroceutical company pursuing multiple clinical applications of its proprietary Nano-Pulse Stimulation technology. Nano-Pulse Stimulation (NPS) is a non-thermal, precise, focal tissue treatment technology comprised of nanosecond (billionth of a second) range pulsed electric fields that directly affect the cell membrane and intracellular structures and initiates cell death in treated cells. The initiation of cell death by NPS results in a minimal inflammatory response, which improves healing outcomes and supports the replacement of treated tissue cells with healthy tissue cells. NPS’ unique mechanism of action to initiate cell death has the potential to significantly benefit patients for multiple medical applications in dermatology, immune-oncology, and in other unique tissue targets. In cancerous lesions, NPS has been shown in preclinical models to induce immunogenic cell death (ICD), which exposes the unique antigens of the treated cells to the immune system and enrolls immune system cells, such as cytotoxic T-cells to mount an adaptive immune response. More information is available at http://www.pulsebiosciences.com.

OFG Bancorp to Report 2Q18 Results and Hold Call on Friday, July 20, 2018

OFG Bancorp (NYSE:OFG) will report second quarter 2018 financial results Friday, July 20, 2018 before the market opens and hold its conference call that morning at 10:00 AM ET.
The call will be accessible live via a webcast on OFG’s website at http://www.ofgbancorp.com. A replay will be available shortly thereafter. Access the webcast link in advance to download any necessary software.Now in its 54th year in business, OFG Bancorp is a diversified financial holding company that operates under U.S. and Puerto Rico banking laws and regulations. Its three principal subsidiaries, Oriental Bank, Oriental Financial Services and Oriental Insurance, provide a wide range of retail and commercial banking, lending and wealth management products, services and technology, primarily in Puerto Rico. Investor information can be found at http://www.ofgbancorp.com.

HomeStreet Announces Preliminary Results from Annual Meeting

HomeStreet, Inc. (Nasdaq:HMST) (the “Company” or “HomeStreet”), the parent company of HomeStreet Bank, today announced that based on the preliminary vote count at the Company’s 2018 Annual Meeting reviewed by its proxy solicitor, all three of the Company’s director nominees, Scott M. Boggs, Douglas I. Smith and Mark R. Patterson, have been reelected to the Company’s Board of Directors. HomeStreet previously indicated that, despite the substantial risk that votes on Roaring Blue Lion’s blue proxy cards would be considered invalid under Washington State banking law, the Company would count votes on blue proxy cards on a provisional basis, subject to the final determination as to the validity of the blue proxy cards. Notably, whether or not votes on blue proxy cards are counted, all of the Board’s nominees were reelected by a majority of the votes cast and all of the Company’s proposals have been approved. Mark K. Mason, President and CEO of HomeStreet, said, “On behalf of the entire Board and management team, I would like to thank our shareholders for their support, as well as the highly valuable input they provided during this process. Our focus at HomeStreet continues to be on executing against our clear strategic plan in order to further diversify our business and deliver shareholder value.“In addition, we are committed to translating the feedback we have received from our shareholders into action. We will continue to evaluate our board composition and corporate governance policies to ensure that we are taking the right steps to position the Company for success. We also appreciate the willingness of our shareholders to engage with the Company in discussing our governance practices over the course of the coming year following proxy season. Most importantly, we look forward to further dialogue with our shareholders – as well as our customers, employees and partners – around how best to maximize the potential of HomeStreet moving forward.” The preliminary voting results also indicate that shareholders approved all other proposals considered at the Company’s 2018 Annual Meeting, including the advisory vote (non-binding) to approve executive compensation, proposal on the advisory (non-binding) vote on the frequency of future advisory shareholder votes on executive compensation and the advisory non-binding ratification of the appointment of the Company’s independent registered public accounting firm. The Company will file the voting results, as tabulated by the independent Inspector of Elections, on a Form 8-K with the Securities and Exchange Commission within four business days.

Telaria To Announce First Quarter 2018 Results on May 7, 2018

Telaria (NYSE:TLRA), a leading video monetization software company, will announce financial results for the first quarter ended March 31, 2018 on Monday May 7, 2018.The Company will host a conference call at 8:00 AM Eastern Time on that date. A press release will be available on the Company’s website prior to the call.Interested parties are invited to listen to the webcast on Telaria’s Investor Relations website at http://investor.telaria.com. The conference call can also be accessed toll-free at (877) 407-9039 or (201) 689-8470 (Toll/International).Following completion of the call, a recorded replay of the webcast will be available on Telaria’s website. To listen to the telephone replay, call toll-free (844) 512-2921 or (412) 317-6671 (Toll/International), replay Pin #: 13678445. The telephone replay will be available from 11:00 AM ET May 7, 2018 through 11:59 PM ET May 14, 2018.
Telaria (NYSE:TLRA) is the leading independent data-driven software platform built to monetize and manage premium video inventory with the greatest speed, control, and transparency, wherever and however audiences are watching.

Cerus to Release First Quarter 2018 Results on May 8, 2018

Cerus Corporation (Nasdaq:CERS) announced today that its first quarter results will be released on Tuesday, May 8, 2018, after the close of the stock market. The company will host a conference call and webcast at 4:15 PM ET that afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook.
To access the live webcast, please visit the Investor Relations page of the Cerus website at http://www.cerus.com/ir.
Cerus Corporation is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action of the INTERCEPT treatment is designed to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, as well as emerging pathogens such as chikungunya, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT Red Blood Cell system is in clinical development.

Quidel to Hold First Quarter 2018 Financial Results Conference Call on May 8, 2018

Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report first quarter 2018 financial results after market close on Tuesday, May 8, 2018.Following the release of results, Douglas Bryant, president and chief executive officer, and Randy Steward, chief financial officer, will host an investment community conference call beginning at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss the results and answer questions. During the conference call, the company will also discuss business and financial developments and trends. The company’s statements may contain or constitute material information that has not been previously disclosed.To participate in the live call by telephone from the U.S., dial 877-930-5791, or from outside the U.S., dial 253-336-7286, and enter the audience pass code 347-4405. A live webcast of the call can be accessed on the Investor Relations section of the Quidel website (http://ir.quidel.com). The website replay will be available for 14 days. The telephone replay will be available for 48 hours beginning at 8:00 p.m. Eastern Time (5:00 p.m. Pacific Time) on May 8, 2018 by dialing 855-859-2056 from the U.S., or by dialing 404-537-3406 for international callers, and entering pass code 347-4405.

Report positive results from two double-blind

Soterix Medical Inc (SMI) is pleased to report positive results from two double-blind, sham-controlled clinical trials of its proprietary transcranial Direct Current Stimulation-Limited Total Energy (tDCS-LTE) technology for the treatment of depression. The Depression tDCS-LTE system is unique in providing drug-free therapy with minimal side effects while maximizing energy delivery to the dorsolateral prefrontal cortex (DLPFC) region, which is implicated in depression control.
The first clinical trial reported tDCS-LTE was an effective, safe, and tolerable add-on intervention in patients with type I or II bipolar disorder in a major depressive episode and receiving a stable pharmacologic regimen. In this 59 patient randomized, sham-controlled, double-blind trial, tDCS-LTE produced an average 14-point improvement in Hamilton Depression Rating Scale (HDRS-17) scores, after just 12 treatments. The benefit persisted for over a month, with common side-effects no different than placebo. The results of the “Bipolar Depression Electrical Treatment Trial [BETTER]” were published in JAMA Psychiatry.The second clinical trial reported tDCS-LTE to be superior to placebo producing an average 8 point decrease in the HDRS-17 after 15 consecutive weekdays of treatment (the induction phase), followed by 7 weekly treatments (the taper phase). In this 245 patient double-blind trial, patients received tDCS-LTE plus oral placebo, sham tDCS-LTE plus escitalopram (an SSRI drug), or sham tDCS-LTE plus oral placebo. The tDCS-LTE group had higher rates of itching or tingling, tinnitus, and nervousness than the other groups. The drug group side-effects included sleeplessness and severe constipation. At the trial endpoint, as the tDCS-LTE dose was tapered to weekly while escitalopram was maintained at a high daily dose, patients who received tDCS-LTE maintained significantly improved HDRS-17 scores compared to placebo while patients on high-dose escitalopram had slightly more improved HDRS-17 with noted side-effects. The results of the “ELECT-tDCS” trial were published in New England Journal of Medicine.
Physicians in the EU, Singapore, Australia, and Brazil interested in providing Soterix Medical Depression tDCS-LTE therapy are eligible for the Soterix Medical’s Partnership program which includes support on the entire patient treatment pipeline, hands-on training and staff certification, and connection to our network of physician researchers.

Viacom Inc. to Report Quarterly Financial Results on April 25, 2018

Viacom Inc. (NASDAQ: VIAB, VIA) announced today that on Wednesday, April 25, 2018, it will issue financial results for the quarter ending March 31, 2018. The company will conduct a conference call at 8:30 a.m. (ET), following the release of its earnings announcement.A live audio webcast of the call will be on the Investor Relations home page of Viacom’s website, beginning at 8:30 a.m. (ET) on April 25. The conference call can also be accessed by dialing 888-715-0404 (domestic) or 918-398-8248 (international). Please call five minutes in advance to ensure that you are connected prior to the call.An audio replay of the call will be available beginning at 12:00 p.m. (ET) on April 25 in the Events/Webcasts section of Viacom’s website, and at 800-585-8367 or 404-537-3406.The earnings release and any other information related to the call will be accessible from the home page of Viacom’s website.
Viacom is home to premier global media brands that create compelling entertainment content – including television programs, motion pictures, short-form content, games, consumer products, podcasts, live events and social media experiences – for audiences in 183 countries. Viacom’s media networks, including Nickelodeon, Nick Jr., MTV, BET, Comedy Central, Paramount Network, VH1, TV Land, CMT, Logo, Channel 5 (UK), Telefe (Argentina), Colors (India) and Paramount Channel, reach approximately 4.3 billion cumulative television subscribers worldwide. Paramount Pictures is a major global producer and distributor of filmed entertainment. Paramount Television develops, finances and produces original programming for television and digital platforms.
For more information about Viacom and its businesses, visit http://www.viacom.com. Keep up with Viacom news by following Viacom’s blog at blog.viacom.com and Twitter feed at http://www.twitter.com/viacom.

Western Union to Release First Quarter Results on May 1, 2018

The Western Union Company (NYSE: WU) announced today that Hikmet Ersek, President and CEO, and Raj Agrawal, Executive Vice President and CFO, will host a webcast and conference call to discuss first quarter 2018 results on May 1, 2018 at 4:30 p.m. Eastern time. A press release highlighting the financial results will be issued at approximately 4:00 p.m. Eastern time the same day.
The Western Union Company (NYSE: WU) is a leader in global payment services. Together with its Vigo, Orlandi Valuta, Pago Facil and Western Union Business Solutions branded payment services, Western Union provides consumers and businesses with fast, reliable and convenient ways to send and receive money around the world, to send payments and to purchase money orders. As of December 31, 2017, the Western Union, Vigo and Orlandi Valuta branded services were offered through a combined network of over 550,000 agent locations in 200 countries and territories and over 150,000 ATMs and kiosks, and included the capability to send money to billions of accounts. In 2017, The Western Union Company completed 276 million consumer-to-consumer transactions worldwide, moving $82 billion of principal between consumers, and 547 million business payments. For more information, visit http://www.westernunion.com.